Literature DB >> 18303076

Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.

Elizabeth J Samelson1, Kerry E Broe, Serkalem Demissie, Thomas J Beck, David Karasik, Sekar Kathiresan, Douglas P Kiel.   

Abstract

OBJECTIVE: Osteoprotegerin (OPG) is an important regulator of bone turnover through its effects on osteoclastogenesis, yet findings from previous studies of circulating OPG and commonly measured bone indices in humans have been conflicting. We conducted a cross-sectional study to evaluate the association between plasma OPG and femoral neck (FN) bone density (BMD) and geometry in a large cohort of women and men.
DESIGN: Participants included 1379 postmenopausal women and 1165 men, aged 50-89 yr (mean, 64 yr), in the Framingham Offspring Study. Dual x-ray absorptiometry was used to evaluate FN BMD and geometry (bone width, section modulus, and cross-sectional area at the narrow neck region). Plasma OPG concentrations were measured by ELISA. Sex-specific analysis of covariance was used to calculate means and assess linear trend in BMD and geometry values across OPG quartiles, adjusted for confounders.
RESULTS: OPG concentrations were greater in women than men, increased with age, and were greater in smokers and those with diabetes and heart disease. Multivariable-adjusted mean FN BMD in women increased from the lowest to the highest OPG quartile (trend, P < 0.01). However, no linear trend between FN BMD and OPG was observed in men (trend, P = 0.34). Section modulus and bone width increased with OPG in men (trend, P < 0.01), whereas no association between hip geometry indices and OPG was observed in women.
CONCLUSION: Higher OPG concentration may indicate greater skeletal strength in women and men, possibly through reducing bone loss in women and increasing periosteal apposition in men.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303076      PMCID: PMC2386280          DOI: 10.1210/jc.2007-2492

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

1.  Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.

Authors:  Y Ichinose; H Tanaka; M Inoue; S Mochizuki; E Tsuda; Y Seino
Journal:  Calcif Tissue Int       Date:  2004-07-30       Impact factor: 4.333

2.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 3.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Authors:  P J Kostenuik; C Capparelli; S Morony; S Adamu; G Shimamoto; V Shen; D L Lacey; C R Dunstan
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.

Authors:  Ki Won Oh; Eun Jung Rhee; Won Young Lee; San Woo Kim; Eun Sook Oh; Ki Hyun Baek; Moo Il Kang; Moon Gi Choi; Hyung Joon Yoo; Sung Woo Park
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

8.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

9.  Correlates of osteoprotegerin levels in women and men.

Authors:  S Khosla; H M Arrighi; L J Melton; E J Atkinson; W M O'Fallon; C Dunstan; B L Riggs
Journal:  Osteoporos Int       Date:  2002-05       Impact factor: 4.507

10.  Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover.

Authors:  Hirokazu Uemura; Toshiyuki Yasui; Yuka Umino; Hirobumi Niki; Masaya Takikawa; Seiichiro Saito; Hiroyuki Furumoto; Minoru Irahara
Journal:  Bone       Date:  2003-11       Impact factor: 4.398

View more
  21 in total

1.  Bivariate genome-wide linkage analysis of femoral bone traits and leg lean mass: Framingham study.

Authors:  David Karasik; Yanhua Zhou; L Adrienne Cupples; Marian T Hannan; Douglas P Kiel; Serkalem Demissie
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

Review 2.  Genetic epidemiology of age-related osteoporosis and its clinical applications.

Authors:  Ching-Lung Cheung; Su-Mei Xiao; Annie W C Kung
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

3.  Physical training increases osteoprotegerin in postmenopausal women.

Authors:  Ingrid Bergström; Paolo Parini; Sven A Gustafsson; Göran Andersson; Jonas Brinck
Journal:  J Bone Miner Metab       Date:  2011-08-09       Impact factor: 2.626

4.  Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.

Authors:  J Coulson; L Bagley; Y Barnouin; S Bradburn; G Butler-Browne; H Gapeyeva; J-Y Hogrel; T Maden-Wilkinson; A B Maier; C Meskers; C Murgatroyd; M Narici; M Pääsuke; L Sassano; S Sipilä; N Al-Shanti; L Stenroth; D A Jones; J S McPhee
Journal:  Osteoporos Int       Date:  2017-06-05       Impact factor: 4.507

5.  Effect of r-Mt-Cpn10 on human osteoblast cells.

Authors:  Yuanyu Zhang; Xia Liu; Kun Li; Jingping Bai
Journal:  Int J Clin Exp Med       Date:  2014-09-15

6.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

7.  Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study.

Authors:  Pawel Szulc; Elizabeth J Samelson; Douglas P Kiel; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

8.  Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study.

Authors:  J Tamaki; M Iki; A Morita; Y Ikeda; Y Sato; E Kajita; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

9.  Serum osteoprotegerin levels are related to height loss: the Tromsø Study.

Authors:  Lone Jørgensen; John-Bjarne Hansen; Jan Brox; Ellisiv Mathiesen; Anders Vik; Bjarne K Jacobsen
Journal:  Eur J Epidemiol       Date:  2011-02-18       Impact factor: 8.082

10.  Relationship between Serum Levels of OPG and TGF- β with Decreasing Rate of BMD in Native Chinese Women.

Authors:  Xi-Yu Wu; Yi-Qun Peng; Hong Zhang; Hui Xie; Zhi-Feng Sheng; Xiang-Hang Luo; Ru-Chun Dai; Hou-De Zhou; Xian-Ping Wu; Er-Yuan Liao
Journal:  Int J Endocrinol       Date:  2013-02-06       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.